Acute and short-term effect of an extra dose of formoterol in COPD patients

Acute and short-term effect of an extra dose of formoterol in COPD patients

Author Studart, Fernando Sérgio Autor UNIFESP Google Scholar
Izbicki, Meyer Autor UNIFESP Google Scholar
Nery, Luiz Eduardo Autor UNIFESP Google Scholar
Oliveira, Luis Vicente Franco Google Scholar
Donner, Claudio F. Google Scholar
Jardim, José Roberto Autor UNIFESP Google Scholar
Nascimento, Oliver Augusto Autor UNIFESP Google Scholar
Institution Mondo Med Multidisciplinary & Rehabil Outpatient
Universidade Federal de São Paulo (UNIFESP)
Nove Julho Univ
Abstract Rationale: Formoterol action may decrease progressively after its inhalation. It is unknown if this decrease of bronchodilation following formoterol use could be associated with worsening hyperinflation.Objectives: To investigate whether the use of an extra daily dose of formoterol could promote a greater reduction in lung hyperinflation and a greater improvement in inspiratory capacity (IC) compared to usual doses.Methods: 56 hyperinflated COPD patients were divided into two groups: F2 and F3. Basal evaluation was carried out after 5 days of formoterol washout. in order to evaluate the acute effect, spirometry and body plethysmography were performed 8 h after the first formoterol dose in both groups and repeated 1 h after an additional formoterol dose (F3) or placebo (F2). the short-term effect was evaluated by measuring the resting lung function after a 14-day period of formoterol t.i.d. (F3) or formoterol b.i.d. + placebo (F2).Measurements and main results: A second formoterol dose inhaled 8 h after the previous dose promoted additional improvements in lung function, as demonstrated by higher IC (118 +/- 140 mL, p < 0.001) and tower functional residual capacity (FRC) (-383 +/- 367 mL, p <0.001). On day 15, the mean differences from baseline regarding all lung function variables were similar between the groups.Conclusion: An extra daily dose of formoterol inhaled 8 h after a previous dose could result in an acute additional peak of bronchodilation. However, short-term formoterol t.i.d. showed no advantages over formoterol b.i.d. concerning reduction of hyperinflation in resting lung function. (C) 2012 Elsevier B.V. All rights reserved.
Keywords COPD
Language English
Sponsor Mantecorp Pharmaceutical Company(R)
Date 2012-06-01
Published in Respiratory Medicine. London: W B Saunders Co Ltd, v. 106, n. 6, p. 853-860, 2012.
ISSN 0954-6111 (Sherpa/Romeo, impact factor)
Publisher W B Saunders Co Ltd
Extent 853-860
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000303429700012

Show full item record


Name: WOS000303429700012.pdf
Size: 430.7Kb
Format: PDF
Open file

This item appears in the following Collection(s)




My Account